- Record: found
- Abstract: not found
- Article: not found
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon ,
Benjamin Besse ,
Todd M Bauer ,
Enriqueta Felip ,
Ross A Soo ,
D Ross Camidge ,
Rita Chiari ,
Alessandra Bearz ,
Chia-Chi Lin ,
Shirish M Gadgeel ,
Gregory J Riely ,
Eng Huat Tan ,
Takashi Seto ,
Leonard P James ,
Jill S Clancy ,
Antonello Abbattista ,
Jean-François Martini ,
Joseph Chen ,
Gerson Peltz ,
Holger Thurm ,
Sai-Hong Ignatius Ou ,
Alice T Shaw
December 2018
December 2018
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d9380343e379">Lorlatinib is a potent, brain-penetrant, third-generation
inhibitor of ALK and ROS1
tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity
was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had
CNS metastases and progression after ALK-directed therapy. We aimed to analyse the
overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive,
advanced non-small-cell lung cancer.
</p>